Rejuvenation Technologies

Rejuvenation Technologies develops therapeutic solutions reversing cellular aging. Its core product uses proprietary technology to safely lengthen telomeres in human cells, aiming to rewind cellular aging by years. This approach targets biological aging at its chromosomal source, employing modified mRNA to activate telomerase, delivered via nanoparticles for precise targeting.

Co-founded by John Ramunas, Glenn Markov, and Helen Blau, the company originated from their foundational telomere biology research, with a key 2015 publication. Stanford PhD Ramunas, a co-inventor, focused doctoral work on telomere extension. Stanford PhD Markov provides genetics expertise. Professor Blau identified short telomeres' role in monogenic diseases.

Rejuvenation Technologies prepares clinical trials for diseases like pulmonary fibrosis and liver disease, linked to short telomeres. Its vision is to transform medicine by preventing or delaying age-related conditions. The company seeks to extend healthy human lifespan by addressing fundamental aging mechanisms.

High-Level Overview

Rejuvenation Technologies is a biotechnology company developing nucleoside-modified TERT mRNA therapeutics delivered via lipid nanoparticles (LNPs) to extend telomeres, rejuvenating cells and addressing age-related diseases like pulmonary fibrosis, liver disease, and bone marrow failure.[1][2][3] Headquartered in Mountain View, California, with about 23 employees, it targets fatal conditions in the liver and lung while pursuing broader healthspan extension, backed by over $10.6M in funding including SBIR/STTR grants and preparations for Series A and clinical trials.[1][2][4][5] The company serves patients with short telomere-driven diseases, solving the core problem of cellular senescence by safely lengthening telomeres in specific tissues to restore regenerative capacity.[3][4]

Origin Story

Founded in 2018 by John Ramunas and Glenn Markov, both with deep expertise in mRNA therapeutics—Ramanas holds a Stanford PhD as co-inventor of the telomere extension tech, with a thesis on extending human healthspan via telomerase.[1][3] Emerging from Stanford University research on nucleoside-modified TERT mRNA, the idea stemmed from decades of studies linking telomere shortening to aging and diseases like pulmonary fibrosis and alcoholic hepatitis.[3][4] Early traction came via SBIR/STTR awards starting in 2020 (3 Phase I, 2 Phase II totaling $4.5M), validating preclinical efficacy in liver regeneration and lung repair, positioning it for clinical advancement.[4]

Core Differentiators

• Breakthrough Telomere Extension Platform: Uses proprietary TERT mRNA and world-leading LNPs for precise, safe telomere lengthening in targeted cells (e.g., lung, liver progenitors), reversing aging markers in hours—validated in rigorous preclinical studies.[1][3][4]
• Tissue-Specific Delivery: Advanced LNP system ensures therapy reaches exact cell types, minimizing off-target effects for diseases like familial pulmonary fibrosis and alcoholic hepatitis.[3][4]
• Accelerated Path to Clinic: Leverages unmet needs for FDA accelerated pathways, with a team boasting bench-to-approval experience; preparing Series A and trials amid $15M+ funding momentum.[2][3][5]
• Broad Applicability: Pipeline starts with fatal diseases but scales to prevent age-related decline (e.g., osteoporosis, Alzheimer's), rooted in fundamental biology of stem cell regeneration.[2][3][4]

Role in the Broader Tech Landscape

Rejuvenation Technologies rides the cellular reprogramming and longevity biotech wave, targeting telomere attrition—a hallmark of aging recognized by sources like the NIH—amid surging investment in anti-aging (e.g., recent $15M raise highlighted in biopharma reports).[2][3][4] Timing aligns with mRNA tech maturation post-COVID vaccines, enabling rapid iteration on regenerative therapies in Silicon Valley's biotech hub, near top institutions.[1][5] Market forces favor it: aging populations drive demand for healthspan extension, with short telomeres implicated in multi-billion-dollar indications like fibrosis ($10B+ market); it influences the ecosystem by pioneering LNP precision for non-viral gene therapies, potentially unlocking treatments for cancer, immunodeficiency, and beyond.[3][4]

Quick Take & Future Outlook

Next steps include Series A closure, IND filings via accelerated paths for pulmonary fibrosis and liver trials, with patient inquiries open—potentially yielding first human data by 2027.[2][3][5] Trends like AI-accelerated drug discovery and multimodal longevity stacks (e.g., pairing with senolytics) will amplify its platform, evolving influence from niche innovator to healthspan leader as telomere therapies validate in clinic.[3] This positions Rejuvenation to transform age-related medicine, directly extending the promise of rewinding cellular clocks for broader human vitality.[1][3]